Syros Pharmaceuticals, Inc.
SYRS
Rank in Stocks
#34449
Syros Pharmaceuticals, Inc. operates as a biopharmaceutical firm primarily... Syros Pharmaceuticals, Inc. operates as a biopharmaceutical firm primarily focused on discovering and developing novel therapeutic solutions for various cancers and monogenic (single-gene) diseases. A key strategic aim for the company involves cultivating a robust pipeline of medicines that modulate gene expression. Its leading investigational drug candidates include: Tamibarotene: A selective retinoic acid receptor alpha agonist, currently undergoing Phase III clinical trials for a genetically defined subset of patients with myelodysplastic syndrome, and in Phase II trials for individuals suffering from acute myeloid leukemia. SY-2101: An innovative oral formulation of arsenic trioxide, intended for the treatment of acute promyelocytic leukemia. SY-5609: A cyclin-dependent kinase 7 inhibitor, which is being assessed in a Phase I clinical study involving patients with specific advanced solid tumors. Syros maintains several strategic alliances, notably a research collaboration and option agreement with Incyte Corporation centered on identifying therapeutic targets for myeloproliferative neoplasms. Furthermore, the company has a licensing arrangement with TMRC Co. Ltd. pertaining to the development and commercialization of tamibarotene. Initially incorporated in 2011 as LS22, Inc., the company officially adopted the name Syros Pharmaceuticals, Inc. in August 2012. Its corporate headquarters are located in Cambridge, Massachusetts.
Share Price
$0.0004
Last synced: 2026-11-09
Market Cap
$10.73K
Change (1 day)
0.00%
Change (1 year)
-50.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Syros Pharmaceuticals, Inc. (SYRS)
Category
Healthcare
Operating Margin for Syros Pharmaceuticals, Inc. (SYRS)
Operating Margin as of November 2026 TTM: -1,298.19%
According to Syros Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is -1,298.19%. At the end of 2023 the company had an operating margin of -1,298.19%.
Operating Margin history for Syros Pharmaceuticals, Inc. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,298.19% | 0.00% |
| 2023 | -1,298.19% | 42.17% |
| 2022 | -913.13% | 115.73% |
| 2021 | -423.28% | -22.37% |
| 2020 | -545.27% | -86.10% |
| 2019 | -3,922.35% | 25.06% |
| 2018 | -3,136.39% | -36.85% |
| 2017 | -4,966.94% | -67.17% |
| 2016 | -15,130.28% | 60.84% |
| 2015 | -9,406.94% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.03% |
US
|
|
| -149.01% | -99.89% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.02% |
BE
|
|
| 29.35% | -100.02% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Syros Pharmaceuticals, Inc.'s operating margin
What is Syros Pharmaceuticals, Inc.'s operating margin?
Syros Pharmaceuticals, Inc.'s operating margin is -1,298.19%, as of Nov 2026.
What was Syros Pharmaceuticals, Inc.'s operating margin in 2023?
In 2023, Syros Pharmaceuticals, Inc.'s operating margin was -1,298.19%, compared with -913.13% in 2022.
How has Syros Pharmaceuticals, Inc.'s operating margin changed since 2018?
From 2018 to 2023, Syros Pharmaceuticals, Inc.'s operating margin was highest in 2021 (-423.28%) and lowest in 2019 (-3,922.35%).
How does Syros Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Syros Pharmaceuticals, Inc.'s operating margin (-1,298.19%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.